Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi(TM) (DFD-29) to Treat Rosacea

Stock Information for Calfrac Well Services

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Calfrac Well Services

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
Sun Pharma to Acquire Checkpoint Therapeutics
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.